https://www.selleckchem.com/pr....oducts/semaxanib-su5
75, 95% CI 0.67-0.82, P less then .00001, I 2 = 11%). There were no statistically significant differences in the efficacy outcomes, including myocardial infarction (RR 0.99, 95% CI 0.79-1.25, P = .96), stent thrombosis (RR 0.97, 95% CI 0.6-1.55, P = .89), ischemic stroke (RR 0.76, 95% CI 0.5-1.15, P = .19), all-cause mortality (RR 1.06, 95% CI 0.85-1.31, P = .61), and MACE (RR 1.06, 95% CI 0.91-1.22, P = .97). Conclusion Compared with triple therapy with VKAS, double therapy with DOACs is associated with a reduced risk of bleed
Like
Comment
Share
